Maria Anderson

536 total citations
10 papers, 423 citations indexed

About

Maria Anderson is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Maria Anderson has authored 10 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Molecular Biology. Recurrent topics in Maria Anderson's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CAR-T cell therapy research (3 papers). Maria Anderson is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CAR-T cell therapy research (3 papers). Maria Anderson collaborates with scholars based in United States, France and Australia. Maria Anderson's co-authors include F. Stephen Hodi, Omid Hamid, John D. Powderly, Daniel S. Chen, Gregg Fine, Marcin Kowanetz, Ahmad Mokatrin, Michael S. Gordon, Jeffrey A. Sosman and Jean‐Charles Soria and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Oncologist.

In The Last Decade

Maria Anderson

10 papers receiving 413 citations

Peers

Maria Anderson

ONCOL

IMMUN

PRM

RNMI

David A. Clump United States

Shinichiro Izawa Japan

Osamu Kawai Japan

J. Erfán Hungary

Xiao Zhao China

Prabhu Bhagavatheeswaran United States

Elena García-Martínez Spain

Elaine Shum United States

Yan Mao China

Tetsuro Taki Japan

David A. Clump United States

Maria Anderson

297 ×0.9

ONCOL

171 ×1.0

IMMUN

80 ×0.7

PRM

149 ×1.8

76 ×1.4

RNMI

Citations per year, relative to Maria Anderson Maria Anderson (= 1×) peers David A. Clump

Countries citing papers authored by Maria Anderson

Since Specialization

Citations

This map shows the geographic impact of Maria Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Anderson more than expected).

Fields of papers citing papers by Maria Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Anderson. The network helps show where Maria Anderson may publish in the future.

Co-authorship network of co-authors of Maria Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Anderson. A scholar is included among the top collaborators of Maria Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Anderson. Maria Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Weekes, Colin D., Lee S. Rosen, Anna Capasso, et al.. (2018). Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 82(2). 339–351. 15 indexed citations

Pawel, Joachim von, David R. Spigel, Thomas J. Ervin, et al.. (2018). Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. The Oncologist. 23(6). 654–e58. 19 indexed citations

García‐Carbonero, Rocio, Eric Van Cutsem, Fernando Rivera, et al.. (2017). Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. The Oncologist. 22(4). 375–e30. 23 indexed citations

Fayette, Jérôme, Lori J. Wirth, Cristina Oprean, et al.. (2016). Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology. 6. 232–232. 84 indexed citations

Anderson, Maria, Kathrin Eliot, P.V. Kelly, & James D. Shoemaker. (2016). Dicarboxylic Acid Excretion in Normal Formula‐Fed and Breastfed Infants. Nutrition in Clinical Practice. 31(6). 819–823. 3 indexed citations

Infante, Jeffrey R., Aaron R. Hansen, Michael J. Pishvaian, et al.. (2016). A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 101–101. 55 indexed citations

Gordon, Michael S., Omid Hamid, John D. Powderly, et al.. (2013). Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Cancer Research. 73(8_Supplement). LB–288. 11 indexed citations

Herbst, Roy S., Michael S. Gordon, Gregg Fine, et al.. (2013). A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Journal of Clinical Oncology. 31(15_suppl). 3000–3000. 157 indexed citations

Powderly, John D., Hartmut Koeppen, F. Stephen Hodi, et al.. (2013). Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. Journal of Clinical Oncology. 31(15_suppl). 3001–3001. 51 indexed citations

10.

Ganguly, Rama, et al.. (1998). Hepatitis B Immunization in a University Student Population. Journal of American College Health. 46(4). 181–183. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact